AR043484A1 - Derivados de 1-tiadibenzozuleno y sus acciones biologicas - Google Patents
Derivados de 1-tiadibenzozuleno y sus acciones biologicasInfo
- Publication number
- AR043484A1 AR043484A1 ARP040100693A ARP040100693A AR043484A1 AR 043484 A1 AR043484 A1 AR 043484A1 AR P040100693 A ARP040100693 A AR P040100693A AR P040100693 A ARP040100693 A AR P040100693A AR 043484 A1 AR043484 A1 AR 043484A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- amino
- alkenyl
- alkynyl
- optionally substituted
- Prior art date
Links
- 230000031018 biological processes and functions Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 3
- 102000000589 Interleukin-1 Human genes 0.000 abstract 2
- 108010002352 Interleukin-1 Proteins 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 abstract 1
- GXMSLNZIHPZWAI-UHFFFAOYSA-N 5-thiatetracyclo[12.4.0.02,6.08,13]octadeca-1(18),2,6,8,10,12,14,16-octaene Chemical class S1CC=C2C3=C(C4=C(C=C12)C=CC=C4)C=CC=C3 GXMSLNZIHPZWAI-UHFFFAOYSA-N 0.000 abstract 1
- -1 C1-alkylsulfonyl -7 Chemical group 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 206010054094 Tumour necrosis Diseases 0.000 abstract 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 150000001356 alkyl thiols Chemical class 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000005021 aminoalkenyl group Chemical group 0.000 abstract 1
- 125000002431 aminoalkoxy group Chemical group 0.000 abstract 1
- 125000005014 aminoalkynyl group Chemical group 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 125000003435 aroyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000005020 hydroxyalkenyl group Chemical group 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 150000003573 thiols Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente se refiere a (a) nuevos derivados de 1-tiadibenzoazuleno de la fórmula (1), (b) a sus ésteres, sales y solvatos farmacológicamente aceptables, (c) a procedimientos e intermediarios para la preparación de los mismos, (d) a un procedimiento para preparar formulaciones farmacéuticas para el tratamiento de enfermedades y condiciones inflamatorias y (e) al uso de los mismos en el tratamiento de enfermedades y condiciones inflamatorias en seres humanos y animales. Estos compuestos inhiben la producción del factor alfa de necrosis tumoral (TNF-alfa) y la producción de la interleucina-1 (IL-1) y tienen una acción analgésica. Reivindicación 1: Un compuesto de la fórmula (1) caracterizado porque: X denota individualmente un heteroátomo -O- o -S-; Y y Z, independientemente uno de otro, denotan individualmente un fragmento de la fórmula (2) -O-(CH2)m-A, en donde A denota individualmente un grupo alquinilo C2-7, alquenilo C2-7 o alquilo C1-7 opcionalmente sustituido, un grupo heterocíclico o heteroarilo, arilo, opcionalmente sustituido, amino, N-(alquilo C1-7)amino, N,N-di(alquilo C1-7)amino; m denota un número entero de 1 a 4; R1 denota individualmente H, halo, un grupo alquinilo C2-7, alquenilo C2-7 o alquilo C1-7 opcionalmente sustituido, un grupo heterocíclico o heteroarilo, arilo opcionalmente sustituido, hidroxi, hidroxi-alquenilo C2-7, hidroxi-alquinilo C2-7, alcoxi C1-7, tiol, tio-alquenilo C2-7, tio-alquinilo C2-7, alquiltiol C1-7, amino, N-(alquilo C1-7)amino, N,N-di(alquilo C1-7)amino, alquilamino C1-7, amino-alquenilo C2-7, amino-alquinilo C2-7, amino-alcoxi C1-7, alcanoilo C1-7, aroilo, oxo-alquilo C1-7, alcanoiloxi C1-7, carboxi, un grupo ariloxicarbonilo o alquiloxicarbonilo C1-7, opcionalmente sustituido, carbamoilo, N-(alquilo C1-7)carbamoilo, N,N-di(alquilo C1-7)carbamoilo, ciano, ciano-alquilo C1-7, sulfonilo, alquilsulfonilo C1-7, sulfinilo, alquilsulfinilo C1-7 y nitro, o un sustituyente de la fórmula (2), en donde los símbolos A y m son definidos más arriba; así como también a ésteres, sales y solvatos farmacológicamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HR20030160A HRP20030160A2 (en) | 2003-03-06 | 2003-03-06 | 1-thiadibenzoazulene derivatives and biological action thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR043484A1 true AR043484A1 (es) | 2005-08-03 |
Family
ID=32947942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040100693A AR043484A1 (es) | 2003-03-06 | 2004-03-05 | Derivados de 1-tiadibenzozuleno y sus acciones biologicas |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20060069149A1 (es) |
| EP (1) | EP1603921B1 (es) |
| JP (1) | JP2006519829A (es) |
| CN (1) | CN1768064A (es) |
| AR (1) | AR043484A1 (es) |
| AT (1) | ATE433983T1 (es) |
| CA (1) | CA2517847A1 (es) |
| CL (1) | CL2004000444A1 (es) |
| DE (1) | DE602004021568D1 (es) |
| HR (1) | HRP20030160A2 (es) |
| WO (1) | WO2004078763A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20020304B1 (en) * | 2002-04-10 | 2008-04-30 | GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. | 1-oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof |
| JP2008532927A (ja) * | 2005-01-13 | 2008-08-21 | グラクソスミスクライン・イストラジヴァッキ・センタル・ザグレブ・ドルズバ・ゼー・オメイェノ・オドゴヴォルノスティオ | 抗炎症マクロライド接合体 |
| US20090221687A1 (en) * | 2005-02-02 | 2009-09-03 | Milan Mesic | Tetracyclic Monoamine Reuptake Inhibitors for Treatment of Cns Diseases and Disorders |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH532038A (de) * | 1970-05-25 | 1972-12-31 | Ciba Geigy Ag | Verfahren zur Herstellung von neuen Cycloheptenderivaten |
| US3859439A (en) * | 1970-05-26 | 1975-01-07 | Ciba Geigy Corp | 2,3-dihydro-5 -trifluoromethyl-1h-dibenzo(2,3:6,7) thiepino (4,5-c) pyrroles as cns-depressants |
| US3711489A (en) * | 1971-03-31 | 1973-01-16 | Pfizer | Certain 8,9-dihydro(3,4,7,8)cycloocta(1,2-d)imidazoles |
| US4112110A (en) * | 1974-02-22 | 1978-09-05 | Ciba-Geigy Corporation | Oxygenated azatetracyclic compounds |
| US3974285A (en) * | 1974-04-10 | 1976-08-10 | Merck & Co., Inc. | 10,11-Furo-derivatives of cyproheptadine |
| US3894032A (en) * | 1974-04-10 | 1975-07-08 | Merck & Co Inc | 10,11-Furo derivatives of cyproheptadine |
| NL7605526A (nl) * | 1976-05-24 | 1977-11-28 | Akzo Nv | Nieuwe tetracyclische derivaten. |
| US4271179A (en) * | 1976-05-24 | 1981-06-02 | Akzona Incorporated | 1,2,3,3a,8,12b-Hexahydro-dibenzo[1,2;5,6]cyclohepta[3,4-C]pyrroles and pharmaceutical use thereof |
| US4198421A (en) * | 1978-11-30 | 1980-04-15 | E. I. Du Pont De Nemours And Company | Antiinflammatory 2-substituted-dibenzo[2,3:6,7]oxepino[4,5-d]imidazoles |
| US4267184A (en) * | 1979-02-08 | 1981-05-12 | E. I. Du Pont De Nemours And Company | Antiinflammatory 4,5-diaryl-2-(substituted-thio)pyrroles and their corresponding sulfoxides and sulfones |
| US4267190A (en) * | 1980-04-18 | 1981-05-12 | E. I. Du Pont De Nemours And Company | Antiinflammatory 4,5-diaryl-α,α-bis(polyfluoromethyl)-1H-pyrrole-2-methanethiols |
| US5840749A (en) * | 1989-08-25 | 1998-11-24 | Hoechst Marion Roussel, Inc. | N-hydroxy-dibenz b,e!oxepinalkylamines, N-hydroxy-dibenz b,e!oxepinalkanoic acid amides and related heterocyclic analogues |
| CA2232141C (en) * | 1996-04-12 | 2006-05-23 | Janssen Pharmaceutica N.V. | Substituted tetracyclic tetrahydrofuran derivatives |
| UA52778C2 (uk) * | 1997-10-10 | 2003-01-15 | Янссен Фармацевтика Н.В. | Галогенозаміщені тетрациклічні похідні тетрагідрофурану, спосіб їх отримання та композиція на їх основі |
| US6471961B1 (en) * | 1999-02-24 | 2002-10-29 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
| US6982089B2 (en) * | 1999-02-24 | 2006-01-03 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
| HRP20000310A2 (en) * | 2000-05-17 | 2002-02-28 | Pliva Farmaceutska Ind Dioniko | New dibenzoazulene compounds as tumor necrosis factor inhibitors |
| HRP20020303B8 (en) * | 2002-04-10 | 2009-03-31 | GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. | Benzonaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
| HRP20020441A2 (en) * | 2002-05-21 | 2003-12-31 | Pliva D D | 1-oxa-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof |
| HRP20020440B1 (en) * | 2002-05-21 | 2008-02-29 | GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. | 1-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof |
-
2003
- 2003-03-06 HR HR20030160A patent/HRP20030160A2/hr not_active Application Discontinuation
-
2004
- 2004-03-05 WO PCT/HR2004/000005 patent/WO2004078763A1/en not_active Ceased
- 2004-03-05 AT AT04717708T patent/ATE433983T1/de not_active IP Right Cessation
- 2004-03-05 JP JP2006506243A patent/JP2006519829A/ja active Pending
- 2004-03-05 EP EP04717708A patent/EP1603921B1/en not_active Expired - Lifetime
- 2004-03-05 CL CL200400444A patent/CL2004000444A1/es unknown
- 2004-03-05 CN CNA2004800085860A patent/CN1768064A/zh active Pending
- 2004-03-05 CA CA002517847A patent/CA2517847A1/en not_active Abandoned
- 2004-03-05 DE DE602004021568T patent/DE602004021568D1/de not_active Expired - Fee Related
- 2004-03-05 AR ARP040100693A patent/AR043484A1/es not_active Application Discontinuation
-
2005
- 2005-09-06 US US11/221,414 patent/US20060069149A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE602004021568D1 (de) | 2009-07-30 |
| WO2004078763A1 (en) | 2004-09-16 |
| HRP20030160A2 (en) | 2005-04-30 |
| US20060069149A1 (en) | 2006-03-30 |
| CA2517847A1 (en) | 2004-09-16 |
| EP1603921B1 (en) | 2009-06-17 |
| ATE433983T1 (de) | 2009-07-15 |
| CN1768064A (zh) | 2006-05-03 |
| JP2006519829A (ja) | 2006-08-31 |
| EP1603921A1 (en) | 2005-12-14 |
| CL2004000444A1 (es) | 2005-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2022000278A (es) | Inhibidores de cisteína proteasas y sus métodos de uso | |
| CL2021002883A1 (es) | Moduladores de thr-ß y métodos de uso de estos | |
| MX2022008066A (es) | Compuestos triciclicos sustituidos. | |
| CR20220312A (es) | Compuestos tricíclicos sustituidos | |
| CO2021000537A2 (es) | Inhibidores de inflamasoma nlrp3 | |
| AR069490A1 (es) | Agonistas de los receptores de glucocorticoides | |
| PE20060648A1 (es) | Procesos para la preparacion de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| CU20110217A7 (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
| UY30641A1 (es) | Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones | |
| BR112012008849A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| EA201070929A1 (ru) | ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ | |
| UY30874A1 (es) | Derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas, su preparacion y su aplicacion en terapéutica. | |
| AR041635A1 (es) | Compuestos de 4-piperazinilbencenosulfonilindoles, preparacion de los mismos y composiciones farmaceuticas que los contienen | |
| PE20090890A1 (es) | Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c | |
| RU2341527C1 (ru) | Аннелированные азагетероциклы, включающие пиримидиновый фрагмент, способ их получения и ингибиторы pi3k киназ | |
| RU2014121205A (ru) | Производные азолов | |
| MX2010009658A (es) | Derivados de azetidina. | |
| PE20220704A1 (es) | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos | |
| MX391410B (es) | Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos. | |
| PE20081703A1 (es) | Nuevos derivados triciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| UY39181A (es) | COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO | |
| AR052938A1 (es) | Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor vr1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure | ||
| FA | Abandonment or withdrawal | ||
| FB | Suspension of granting procedure |